Table 1.
Characteristics of studies included in this meta-analysis for H19.
| Author | Year | Country | Tumor type | Sample | Sample size | Cut-off value |
|---|---|---|---|---|---|---|
| Zhang [3] | 2014 | China | GC | Tissue | 80 | Mean |
| Zhang [21] | 2016 | China | NSCLC | Tissue | 70 | Median |
| Arita [22] | 2013 | Japan | GC | Plasma | 43 | 0.32 |
| Wang [11] | 2015 | China | RCC | Tissue | 92 | 3.8-fold change |
| Wang [23] | 2016 | China | GBC | Tissue | 20 | NA |
| You [24] | 2014 | China | GC | Tissue | 30 | Median |
| Esteves [25] | 2005 | Brazil | HNSCC | Tissue | 35 | Absence/presence |
| Huang [26] | 2015 | China | EC | Tissue | 133 | Median |
| Chen [27] | 2016 | China | GC | Tissue | 128 | Median |
| Zhu [28] | 2015 | China | OC | Tissue | 70 | NA |
| Tan [29] | 2016 | China | EC | Tissue | 64 | NA |
| Wang [30] | 2016 | China | GBC | Tissue | 24 | Median |
| Han [31] | 2016 | China | CRC | Tissue | 83 | 3.8-fold change |
GC: gastric cancer, NSCLC: non-small-cell lung cancer, RCC: renal cell carcinoma, GBC: gallbladder cancer, HNSCC: head-and-neck squamous cell carcinomas, EC: esophageal cancer, OC: ovarian cancer, and CRC: colorectal cancer.